Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma
2008-000748-14Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzastaurin in Waldenström macroglobulinemia (WM) and multiple myeloma (MM), sponsored by Eli Lilly and Company. Primary endpoints: Response rate to single-agent enzastaurin and Estimated response rate by disease subgroup. Started Apr 2008; status: completed.
02
Drugs
enzastaurin
03
Conditions
Waldenström macroglobulinemia (WM)multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-000748-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000748-14.